Atreca

IRS: 273723255
BCEL

Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. It has single segment business of therapeutic drug discovery and development. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Founded
2010 (13 years)
Investor RelationsSEC
Revenue
0 (2022)

Want to see more? Sign up!